Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Medium Chain Triglycerides (MCTs) have some scientific rationale for use in supporting patients with Inflammatory Bowel Disorders (IBD), such as Crohn’s disease and ulcerative colitis, but the evidence is limited and not definitive. MCTs are fats that are more easily digested and absorbed than long-chain triglycerides, as they do not require bile salts for absorption and are transported directly to the liver via the portal vein. This property is particularly relevant in IBD, where intestinal inflammation can impair fat absorption. Several small studies and clinical observations have suggested that MCTs can help improve fat and nutrient absorption in individuals with malabsorption due to IBD, especially in patients who have had significant bowel resection or who experience steatorrhea.

However, while there are physiological reasons for using MCTs in IBD, robust clinical evidence supporting their use as a treatment for the underlying inflammatory process is lacking. Most research focuses on their role in nutritional support rather than as an anti-inflammatory therapy. Some animal studies and preliminary clinical data suggest MCTs may have modulatory effects on gut immunity or microbiota, but results are inconsistent and not conclusive. Therefore, the use of MCTs in IBD is mainly as a supportive nutritional intervention rather than a primary therapy for inflammation, and the overall quality of evidence is low to moderate.

More about Medium Chain Triglycerides
More about Inflammatory Bowel Disorders

Other ingredients used for Inflammatory Bowel Disorders

Other health conditions supported by Medium Chain Triglycerides

Products containing Medium Chain Triglycerides